Theravance Biopharma
TBPH
125 hedge funds and large institutions have $1.11B invested in Theravance Biopharma in 2020 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 13 closing their positions.
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
50% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 28
19% more funds holding
Funds holding: 105 → 125 (+20)
6.38% less ownership
Funds ownership: 90.32% → 83.95% (-6.4%)
15% less capital invested
Capital invested by funds: $1.32B → $1.11B (-$203M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
96% less call options, than puts
Call options by funds: $39K | Put options by funds: $1.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$60.2M |
| 2 |
Jane Street
New York
|
+$31.3M |
| 3 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$11.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$113M |
| 2 |
PA
Perceptive Advisors
New York
|
-$23.1M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.03M |
| 4 |
Morgan Stanley
New York
|
-$3.73M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.46M |
TBPH Hedge Fund Activity: Q2 2020 in Review
125 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2020, worth a combined $1.11B — down 15% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TBPH positions and 13 closed out — a net gain of 22 holders — while 42 added to existing stakes and 28 trimmed.
The largest buyer was OrbiMed, adding an estimated $60.2M. The largest seller was BlackRock, cutting an estimated $113M.
- 125 institutional investors held Theravance Biopharma (TBPH) as of Q2 2020, up from 105 in Q1 2020.
- Funds reported $1.11B of Theravance Biopharma stock for Q2 2020, down 15% quarter-over-quarter.
- 35 funds opened new Theravance Biopharma positions in Q2 2020 and 13 closed out, a net change of +22 holders.
- The largest Theravance Biopharma buyer in Q2 2020 was OrbiMed, an estimated $60.2M added.
- The largest Theravance Biopharma seller in Q2 2020 was BlackRock, an estimated $113M sold.
Based on aggregated 13F filings for Q2 2020.